M&T Bank Corp Sells 147,548 Shares of Gilead Sciences, Inc. $GILD

Key Points

• M&T Bank Corp cut its stake in Gilead by 86.5% in Q4, selling 147,548 shares and leaving 23,088 shares valued at about $2.83 million per its 13F filing.
• Gilead beat Q results (EPS $1.86 vs $1.83; revenue $7.93B vs $7.68B), issued FY2026 EPS guidance of 8.45–8.85, and raised its quarterly dividend to $0.82 (annualized $3.28, ~2.6% yield).
• Company insiders have sold shares recently (CEO sold 10,000; CFO sold 3,000), while Wall Street remains mostly positive with 24 Buy and 4 Hold ratings and an average target of about $157.35.

M&T Bank Corp lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 86.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,088 shares of the biopharmaceutical company's stock after selling 147,548 shares during the period. M&T Bank Corp's holdings in Gilead Sciences were worth $2,834,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Csenge Advisory Group increased its holdings in Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company's stock valued at $2,375,000 after purchasing an additional 16,288 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in Gilead Sciences by 52.1% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company's stock valued at $8,713,000 after purchasing an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. increased its holdings in Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company's stock valued at $1,115,000 after purchasing an additional 7,168 shares during the period. Railway Pension Investments Ltd increased its holdings in Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company's stock valued at $157,139,000 after purchasing an additional 42,200 shares during the period. Finally, TriaGen Wealth Management LLC purchased a new position in Gilead Sciences during the 3rd quarter valued at about $1,274,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 2.0%

GILD stock opened at $127.75 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $95.29 and a fifty-two week high of $157.29. The business's 50 day moving average price is $141.90 and its two-hundred day moving average price is $132.30. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company has a market capitalization of $158.57 billion, a price-to-earnings ratio of 18.87, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm's quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Friday, March 13th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio (DPR) is currently 48.45%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Truist Financial upped their target price on Gilead Sciences from $145.00 to $152.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a "buy" rating in a report on Wednesday, February 11th. Scotiabank upped their target price on Gilead Sciences from $140.00 to $177.00 and gave the stock a "sector outperform" rating in a report on Wednesday, February 11th. Morgan Stanley upped their target price on Gilead Sciences from $171.00 to $175.00 and gave the stock an "overweight" rating in a report on Friday, April 10th. Finally, Barclays assumed coverage on Gilead Sciences in a report on Friday, February 20th. They set an "equal weight" rating and a $155.00 target price on the stock. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $157.35.

Insider Buying and Selling

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the sale, the chief executive officer owned 642,308 shares in the company, valued at $92,999,775.32. This represents a 1.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares in the company, valued at $24,835,883.36. The trade was a 1.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,640 shares of company stock worth $26,691,550 in the last 90 days. Insiders own 0.30% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.